Welestra D Tablet contains a combination of Ethinyl Estradiol (0.02 mg) and Desogestrel (0.15 mg), which are synthetic hormones used primarily for oral contraception. Ethinyl Estradiol is a synthetic estrogen, while Desogestrel is a progestin, both working synergistically to prevent ovulation, alter the cervical mucus to hinder sperm penetration, and modify the endometrial lining to prevent implantation. This low-dose combined oral contraceptive is indicated for the prevention of pregnancy in women of reproductive age. Welestra D is typically administered once daily, ideally at the same time each day, to maintain effective hormone levels and optimize contraceptive efficacy. It is important to start the medication according to the prescribed schedule and to use additional contraceptive methods during the initial seven days of the first cycle. Patients should be counseled on potential side effects, including nausea, headache, breast tenderness, and breakthrough bleeding. Contraindications include a history of thromboembolic disorders, estrogen-dependent neoplasms, uncontrolled hypertension, and liver disease. Regular medical evaluation is recommended to monitor blood pressure and assess any adverse reactions. Welestra D should be used under medical supervision, with adherence to prescribed guidelines to ensure safety and effectiveness in contraception.